PMID- 21756958
OWN - NLM
STAT- MEDLINE
DCOM- 20120111
LR  - 20221207
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 72
IP  - 10
DP  - 2011 Oct
TI  - Human leukocyte antigen class I polymorphisms influence the mild clinical 
      manifestation of Plasmodium falciparum infection in Ghanaian children.
PG  - 881-8
LID - 10.1016/j.humimm.2011.06.007 [doi]
AB  - A prospective study that included 429 children for active detection of mild 
      malaria was conducted in a coastal region of Ghana to reveal whether the 
      incidence of malaria is affected by human leukocyte antigen (HLA) polymorphism. 
      During 12 months of follow-up, 85 episodes of mild clinical malaria in 74 
      individuals were observed, and 34 episodes among them were accompanied with 
      significant parasitemia at >5000 infected red blood cells per cubic millimeter. 
      Attributable and relative risks conferred by genetic factors in the HLA region 
      were evaluated by comparison of the incidence in children, stratified by carrier 
      status, of a given allele of HLA-A, -B, -DRB1 and TNFA promoter polymorphism. 
      HLA-B*35:01 reduced the incidence by 0.178 events per person per year (0.060 
      versus 0.239 for B*35:01-positive and -negative subpopulations, respectively), 
      and a relative risk of 0.25, which remained statistically significant after 
      Bonferroni's correction for multiple testing (p(c) = 8.2 x 10(-5)). Further, 
      HLA-B*35:01 and -B*53:01 exhibited opposite effects on the incidence of malaria 
      with significant parasitemia. When parasite densities in different HLA carriers 
      status were compared, HLA-A*01 conferred an increase in parasite load (p = 6.0 x 
      10(-7)). In addition, we found a novel DRB1 allele that appears to have emerged 
      from DRB1*03:02 by single nucleotide substitution.
CI  - Copyright (c) 2011 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Yamazaki, Akiko
AU  - Yamazaki A
AD  - Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki 
      University, Nagasaki, Japan.
FAU - Yasunami, Michio
AU  - Yasunami M
FAU - Ofori, Michael
AU  - Ofori M
FAU - Horie, Hitomi
AU  - Horie H
FAU - Kikuchi, Mihoko
AU  - Kikuchi M
FAU - Helegbe, Gideon
AU  - Helegbe G
FAU - Takaki, Akiko
AU  - Takaki A
FAU - Ishii, Kazunari
AU  - Ishii K
FAU - Omar, Ahmeddin Hassan
AU  - Omar AH
FAU - Akanmori, Bartholomew D
AU  - Akanmori BD
FAU - Hirayama, Kenji
AU  - Hirayama K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110701
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Alleles
MH  - *Black People
MH  - Child
MH  - Child, Preschool
MH  - *Disease Susceptibility
MH  - Female
MH  - Gene Frequency
MH  - Genetic Association Studies
MH  - Genotype
MH  - Ghana/epidemiology
MH  - HLA-A Antigens/analysis/genetics/immunology
MH  - HLA-B Antigens/analysis/genetics/immunology
MH  - HLA-DRB1 Chains/analysis/genetics/immunology
MH  - Histocompatibility Testing/*methods
MH  - Humans
MH  - Incidence
MH  - Leukocytes/chemistry/cytology/*immunology
MH  - Malaria, Falciparum/ethnology/*genetics/immunology/parasitology/physiopathology
MH  - Male
MH  - Parasite Load
MH  - Phenotype
MH  - Plasmodium falciparum/*physiology
MH  - *Polymorphism, Genetic/immunology
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Tumor Necrosis Factor-alpha/analysis/genetics/immunology
EDAT- 2011/07/16 06:00
MHDA- 2012/01/12 06:00
CRDT- 2011/07/16 06:00
PHST- 2011/03/01 00:00 [received]
PHST- 2011/06/13 00:00 [revised]
PHST- 2011/06/27 00:00 [accepted]
PHST- 2011/07/16 06:00 [entrez]
PHST- 2011/07/16 06:00 [pubmed]
PHST- 2012/01/12 06:00 [medline]
AID - S0198-8859(11)00153-4 [pii]
AID - 10.1016/j.humimm.2011.06.007 [doi]
PST - ppublish
SO  - Hum Immunol. 2011 Oct;72(10):881-8. doi: 10.1016/j.humimm.2011.06.007. Epub 2011 
      Jul 1.